

NEOTHERAPEUTICS INC

Form 8-K

October 30, 2001

**Table of Contents**

**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(D) OF THE  
SECURITIES AND EXCHANGE ACT OF 1934**

October 30, 2001

Date of Report (Date of earliest event reported)

---

**NEOTHERAPEUTICS, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other Jurisdiction  
of Incorporation)

**000-28782**  
(Commission File Number)

**93-0979187**  
(IRS Employer  
Identification Number)

**157 Technology Drive**  
**Irvine, California**  
(Address of principal executive offices)

**92618**  
(Zip Code)

**(949) 788-6700**  
(Registrant's telephone number, including area code)

N/A  
(Former Name or Former Address, if Changed Since Last Report)

---

**TABLE OF CONTENTS**

Item 5. Other Events.

Item 7. Exhibits

SIGNATURES

EXHIBIT INDEX

Exhibit 99.1

**Item 5. Other Events.**

On October 30, 2001, NeoTherapeutics, Inc. issued a news release regarding modifications to the data analysis schedule of the company's Alzheimer's disease clinical trial of its lead drug candidate, Neotrofin™, that is currently in progress. The text of the press release is set forth in Exhibit 99.1 attached to this report and incorporated herein by this reference.

**Item 7. Exhibits**

Exhibits:

99.1 Press Release dated October 30, 2001.

---

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NEOTHERAPEUTICS, INC.

Date: October 30, 2001

By: /s/ Samuel Gulko

Name: Samuel Gulko

Title: Senior Vice President, Finance,  
Chief Financial Officer, Secretary and Treasurer

**Table of Contents**

\

**EXHIBIT INDEX**

<u>Exhibit Number</u>	<u>Document Description</u>
99.1	Press Release dated October 30, 2001.